News archives

Home > News archives

Completion of the Series C funding to advance pipeline of novel GPCR antibodies

Apr 27,2022 -- Updated 22:50 +0900 (GMT)

NBHL has completed 7.64 million USD of the Series C funding to advance pipeline of novel GPCR antibodies.

Click here for detail.

Announcement of a grant of patent for innovative new high-throughput single-cell analysis technology in US 2022.03.29.

Mar 31,2022 -- Updated 10:20 +0900 (GMT)

We are pleased to inform you that the patent we applied for the new drug candidate search technology has been granted in the United States.

This patent is regarding a technique for selecting cells that produce a target substance that specifically binds to a cell membrane protein more quickly and efficiently, and a technique relating to a novel single-cell analysis technology (Rapid isolation of GPCR-specific Antibody by Single-cell Screening System: RiGRASSTM) that produces target substances such as antibodies using cells selected by foregoing technology.

[US Patent Application Number] US 17 / 431,268

[Public number] WO2020 / 171020

[Assessment date] March 24, 4th year of Reiwa (2022.3.24)

[Title of the invention]

Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent

We are now able to evaluate antibodies that specifically bind to the G protein-coupled receptor (GPCR) targeted for drug discovery in a shorter period of time than more antibody-producing B cells. We will continue to promote the development of therapeutic agents for antibodies that bind to and act on GPCRs, which have been said to be difficult to obtain.

NBHL will participate in BIO-Europe Spring 2022 – Digital.

Mar 9,2022 -- Updated 11:02 +0900 (GMT)

NBHL will participate in BIO-Europe Spring 2022 – Digital to be held from March 28th through March 31st ( in a digital format. BIO-Europe Spring is organized by the EBD Group.  We are looking forward to meeting you in virtual partnering meetings to discuss future opportunities on our antibody technology and development pipeline.

For more information on this event, please visit

https://informaconnect.com/bioeurope-spring/

NBHL will participate in GLOBAL START UP CONNECTION JAPAN and Digital RESI

Mar 9,2022 -- Updated 11:01 +0900 (GMT)

NBHL will participate in GLOBAL START UP CONNECTION JAPAN (March 10, 2022) and Digital RESI (March 22-24, 2022), respectively.

We are looking forward to meeting you in virtual partnering meetings to discuss investment and/or alliance opportunities on our antibody technology and development pipeline.

The 1st event GLOBAL START UP CONNECTION JAPAN

Date       : Thursday March 10th, 2022

Organizer : Ministry of Economy, Trade and Industry

For more information on this event, please visit https://gsc2022-japan.jp/

 

The 2nd event Digital RESI March

Date       : Tuesday March 22nd through Thursday March 24th (EST)

Tuesday March 22nd midnight Friday March 25th early morning (JST)

Organizer : LIFE SCIENCE NATION, LLC

For more information on this event, please visit https://resiconference.com/

NBHL will participate in Botech Showcase (Vertual).

Jan 4,2022 -- Updated 17:09 +0900 (GMT)

NBHL will participate in Biotech Showcase 2022 – Digital to be held from January 10–12, 2022 & January 17–19. We are looking forward to meeting you in virtual partnering meetings to discuss investment and/or alliance opportunities on our antibody technology and development pipeline.

For more information on this event, please visit https://informaconnect.com/biotech-showcase/

 

  • The event dates will remain the same, January 10–12, 2022 and January 17–19, 2022
  • One-to-one meetings for January 10–12, 2022 will now be held virtually and expanded to a 24-hr timeframe to accommodate and facilitate meetings with delegates from around the world
  • All event content, company presentations and program sessions will now be hosted on partneringONE® providing you with one-stop access to everything with ONE login

Closing of the Series C funding to advance pipeline of novel GPCR antibodies

Aug 24,2021 -- Updated 16:32 +0900 (GMT)

NBHL has closed the Series C funding to advance pipeline of novel GPCR antibodies.

Click here for detail.

Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies

Aug 24,2021 -- Updated 16:31 +0900 (GMT)

NBHL has singed the Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies.

Click here for details.

NBHL will participate in BIO-Europe 2020 – Digital.

Oct 23,2020 -- Updated 18:04 +0900 (GMT)

NBHL will participate in BIO-Europe 2020 – Digital to be held from October 26th to 29th, 2020. We are looking forward to meeting you in virtual partnering meetings to discuss future opportunities on our antibody technology and development pipeline. 

For more information on this event, please visit https://ebdgroup.knect365.com/bioeurope/

 

NBHL will be present at BioJapan 2020 in Yokohama, Japan

Oct 14,2020 -- Updated 10:43 +0900 (GMT)

NBHL will have a panel exhibition at C-13 (in Hokkaido & Sapporo Bio Consortium booth) in “BioJapan 2020” to be held in Pacifico Yokohama, Japan, from October 14th to 16th, 2020. We are looking forward to meeting you via online one-on-one partnering.

For more information on this event, please visit https://www.ics-expo.jp/biojapan/en/

NBHL will participate in BioPharm America 2020 – Digital

Sep 18,2020 -- Updated 19:24 +0900 (GMT)

NBHL will participate in BioPharm America 2020 – Digital to be held from September 21st to 24th, 2020. We are looking forward to meeting you in virtual partnering meetings to discuss future opportunities.

For more information on this event, please visit https://informaconnect.com/biopharm-america/

次へ »